NCT01926899已完成1 期
A Multicenter Phase I Study Evaluating the Addition of Bortezomib to an Established Acute Graft Versus Host Disease (aGVHD) Prophylaxis Regimen in Pediatric Allogeneic Hematopoietic Stem Cell Transplant (Allo HSCT) Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 15
- 试验地点
- 2
- 主要终点
- Maximum tolerated dose of bortezomib
研究概览
简要总结
The objective of this study is to determine the maximum tolerated dose (MTD) of bortezomib in combination with calcineurin inhibitor and methotrexate as acute graft versus host disease (aGVHD) prophylaxis in pediatric patients undergoing allogeniec hematopoietic stem cell transplant (alloHSCT)
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 1 Year 至 21 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.
- •Female subject of childbearing potential agree to practice 2 effective methods of contraception from the time of signing the informed consent form through 30 days after the last dose of bortezomib, or agree to completely abstain from heterosexual intercourse.
- •Male subjects, even if surgically sterilized (i.e., status postvasectomy) must agree to 1 of the following: practice effective barrier contraception during the entire study treatment period and through a minimum of 30 days after the last dose of study drug, or completely abstain from heterosexual intercourse.
- •Subjects must be greater than or equal to 1 years old and less 22 years old.
- •Subjects must have any malignant or non-malignant condition that requires treatment with alloHSCT
- •Karnofsky or Lansky performance score greater than 60%
- •Subjects must have a 9 of 10 (HLA A, B, C, DR, and DQ) or 10 of 10 HLA matched-related or MUD for bone marrow or peripheral blood alloHSCT
- •Subjects must meet other institutional criteria for alloHSCT
排除标准
- •• Patient has greater than 1.5 times upper limit normal (ULN) Total Bilirubin
- •Patient has greater than or equal to Grade 2 peripheral neuropathy
- •Patient had myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at screening must be documented by the investigator as not medically relevant.
- •Patient has hypersensitivity to bortezomib, boron, or mannitol.
- •Female subject is pregnant or lactating. Confirmation that the subject is not pregnant must be established by a negative serum beta-human chorionic gonadotropin (beta hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for postmenopausal or surgically sterilized women.
- •Female patients who are lactating or have a positive serum pregnancy test during the screening period, or a positive urine pregnancy test on Day 1 before first dose of study drug, if applicable.
- •Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
- •Diagnosed or treated for another malignancy within 2 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy.
- •Participation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trial.
- •Radiation therapy within 3 weeks before randomization. Enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 3 weeks have elapsed since the last date of therapy.
- •Current active infection per physician determination
- •HIV positive
- •Previous myeloablative autoHSCT or alloHSCT in previous 12 months
- •ALT and AST greater than 5 times ULN for age
- •Creatinine clearance or glomerular filtration rate (GFR) less than 60 ml/min/1.73
- •Shortening fraction less than 26% or ejection fraction less than 45%
- •Diffusing capacity of carbon monoxide (DLCO), volume exhaled at end of first second of forced expiration (FEV1), diffusion capacity less than 50% of predicted (corrected for hemoglobin); if unable to perform lung function tests, oxygen saturation less than 94% on room air
研究组 & 干预措施
Bortezomib administration
Experimental
0.7 milligrams per meter squared given on Day 0 and Day +3
干预措施: Bortezomib administration (Drug)
结局指标
主要结局
Maximum tolerated dose of bortezomib
时间窗: 100 days post transplant
次要结局
未报告次要终点
研究者
David Delgado
Clinical Director of Pediatric Stem Cell Transplant
Indiana University
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MMMultiple MyelomaNCT01114282Stanford University11
已完成
1 期
Study Combining Bortezomib With High Dose Melphalan to Treat Multiple MyelomaMultiple MyelomaNCT00784823Hackensack Meridian Health32
已完成
1 期
Phase I Using Velcade & Idarubicin in Elderly and Relapsed AMLAcute Myelogenous LeukemiaNCT00382954University of Kentucky55
已完成
1 期
A Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT)Multiple MyelomaNCT00985959Janssen Pharmaceutical K.K.101
终止
2 期
A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's LymphomaFollicular LymphomaNCT00479167Rush University Medical Center1